HLXB SEC filings, in plain English
Everything Helix Acquisition Corp. II has filed with the SEC that we hold — 40 filings, newest first, 2 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
pipenothing moved · 1 with no prior record of ours
- PIPE
- not previously extracted$260.9M
The clause …“shares of its common stock to investors in a private placement financing (“PIPE Financing”) for an aggregate purchase price of approximately $260.9 million, which was executed immediately prior to the Closing. The de-SPAC Transaction”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: The 10-Q filed under Commission file number 001-41955 is that of BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) for the quarter ended June 30, 2026, with 80,174,267 shares outstanding as of August 6, 2026. Cash and equivalents fell to $54,063 thousand from $373,687 thousand as $171,648 thousand of short-term and $118,419 thousand of long-term marketable securities were built up; total assets were $376,706 thousand against $448,381 thousand. Why it matters: The cash fall of $319.6 million is a reallocation into marketable securities rather than a burn — total assets fell $71.7 million over six months, which is closer to the $98.6 million half-year loss. The per-share figures as printed are off by a factor of a thousand against the same statement's own share count, so they should not be quoted from this filing.
pipenothing moved · 1 with no prior record of ours
- PIPE
- $260.9M · unchanged
The clause …“shares of its common stock to investors in a private placement financing (“PIPE Financing”) for an aggregate purchase price of approximately $260.9 million, which was executed immediately prior to the Closing. The de-SPAC Transaction”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: BridgeBio Oncology Therapeutics, Inc. (BBOT), the successor to Helix Acquisition Corp. II, called its 2026 annual meeting for Tuesday, June 16, 2026 at 1:00 p.m. Pacific Daylight Time, virtual, record date April 20, 2026, with 80,112,725 shares of common stock outstanding. Holders elect two Class I directors to serve until 2029 and ratify Deloitte & Touche LLP for the fiscal year ending December 31, 2026. Helix consummated the business combination on August 11, 2025 under a business combination agreement dated February 28, 2025 and amended June 17, 2025. Why it matters: This is the first annual meeting after the August 11, 2025 closing, so the Helix II trust has been released and no redemption right or per-share floor survives for legacy SPAC holders. From here the 80.1 million shares are backed only by the oncology pipeline; the amended-then-closed deal timeline shows the transaction required renegotiation four months before closing, which is worth remembering when reading later disclosure about deal terms.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.